Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

被引：0
|
作者：
Perkovic, Vlado [1 ]
Kollins, Dmitrij [2 ]
Papachristofi, Olympia [2 ]
Hach, Thomas [2 ]
Jacinto-Sanders, Severina [2 ]
Merkel, Tobias [2 ]
Renfurm, Ronny [2 ]
Rizk, Dana V. [3 ]
机构：
[1] Univ New South Wales, Sydney, NSW, Australia
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Alabama Birmingham, Div Nephrol, Dept Med, Birmingham, AL USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
456
引用
收藏
页码：I255 / I256
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY
    Rizk, Dana V.
    Kollins, Dmitrij
    Papachristofi, Olympia
    Hach, Thomas
    Jacinto-Sanders, Severina
    Merkel, Tobias
    Renfurm, Ronny
    Perkovic, Vlado
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (05) : 699 - 700
  • [2] Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
    Rizk, Dana, V
    Rovin, Brad H.
    Zhang, Hong
    Kashihara, Naoki
    Maes, Bart
    Trimarchi, Hernan
    Perkovic, Vlado
    Meier, Matthias
    Kollins, Dmitrij
    Papachristofi, Olympia
    Charney, Alan
    Barratt, Jonathan
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (05): : 968 - 979
  • [3] Interim analysis of a Phase 2 dose ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy
    Meier, Matthias
    Barratt, Jonathan
    [J]. SWISS MEDICAL WEEKLY, 2021, 151 : 2S - 2S
  • [4] A Phase 2a Study to Evaluate the Safety and Efficacy of Tegoprubart (AT-1501) in Patients With IgA Nephropathy (IgAN)
    Barratt, Jonathan
    Liew, Adrian
    Rizk, Dana
    Willcocks, Lisa
    Lafayette, Richard A.
    Wong, Muh Geot
    Tesar, Vladimir
    Bornstein, Jeffrey D.
    Reich, Heather N.
    Tang, Sydney C.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 187 - 188
  • [5] INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN)
    Barratt, Jonathan
    Leifke, Eckhard
    Whitaker, Steve
    DeTulleo, Louis
    Lafayette, Richard
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [6] UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
    Barratt, Jonathan
    Kooienga, Laura
    Agha, Irfan
    Ruiz-Ramon, Pablo
    Madan, Arvind
    Thomas, Hanna
    Sorensen, Bess
    Leiske, Jocelyn
    Khawaja, Zeeshan
    King, Andrew
    Jones-Burton, Charlotte
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I394 - I394
  • [7] Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients With IgA Nephropathy
    Barratt, Jonathan
    Kooienga, Laura
    Agha, Irfan
    Thomas, Hanna
    Workeneh, Biruh
    Iyer, Sai Prasad N.
    Narayanan, Rangaraj
    Sathaliya, Taher
    Sorensen, Bess
    Schwartz, Brian S.
    King, Andrew J.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 503 - 503
  • [8] Efficacy and Safety of Facilitated Subcutaneous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Disease: Interim Analysis of a Phase 3 Study in the USA
    Patel, Niraj
    Walter, Jolan
    Wasserman, Richard
    Rubinstein, Arye
    Atkinson, T. Prescott
    Shepherd, Meagan
    Greco, Erin
    Russo-Schwarzbaum, Sara
    Saeed-Khawaja, Shumyla
    Mccoy, Barbara
    Yel, Leman
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S50 - S51
  • [9] Efficacy and Safety of Hydroxychloroquine in Patients with IgA Nephropathy: A Meta-Analysis
    Zhang, Zhe
    Liu, Xiaoyi
    Ye, Peiyi
    Xie, Chao
    Kong, Yaozhong
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2024, 77 (01): : 16 - 24
  • [10] Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis
    Qian, Ge
    Zhang, Xiaoyu
    Xu, Weicheng
    Zou, Hequn
    Li, Yongqiang
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (05) : 859 - 868
12345